fda warning letter hims compounded semaglutide 2025 & Hers compounder received letter| STAT FDA alerts health care providers,
Description
As these weight-loss medications have gained popularity potentially helping obesity rates drop for the first time in a decade theyve also seemed to reduce patients alcohol use, too
Real relationships
Wegovy prescriptions are typically written by primary care or obesity medicine providers who dont compound or work with compounding pharmacies
No, GLP-1 receptor agonists are not approved by the MHRA for treating alcohol use disorder
Hers also offers brand-name GLP-1s, though at higher out-of-pocket costs
